Emmessar Biotech & Nutrition Ltd.
Snapshot View

49.50 +2.35 ▲5.0%

26 July 2021, 04:00:00 P.M.
Volume: 2,058

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ebnl.org
Financial Indicators
Market Cap 24.73 Cr.
Earnings per share (EPS) 2.90 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 17.07 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 11.41 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.34 Calculated using Price: 49.50
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.50 Cr. 4,996,100 Shares
FaceValue 10
Company Profile

Emmessar Biotech & Nutrition Ltd., was originally started as Emmessar Chemical Industries Ltd on  March 17,1992, for manufacturing Super Speciality Fine Chemicals. The Company succeeded in developing many Speciality Fine Chemicals in its own In-house R&D, which was recognised on  January 15, 1996 by DSIR, Ministry of Science & Technology, Government of India, New Delhi .

When there was a realisation that some of the Speciality Chemicals developed in our R&D and exported to USA & Europe were being used in Healthcare formulations, the Company decided to re-orient itself and enter the Healthcare business, which is poised for phenomenal growth in the coming decades.

Concurrently the company also realised that some of the Speciality Chemicals are actually Vital Micro Nutrients, which are being used in the research worldwide as tools of Biotechnology, the Company took a conscious decision to enter the field of Biotechnology & Healthcare.

To ensure that the name is representative of its activity, the company's name was changed from Emmessar Chemical Industries Ltd., to Emmessar Biotech & Nutrition Ltd., on 7th April 2000.

In the process of pursuing its own R&D and exploring commercial market potentials for their products in the field of Healthcare, the company came across another reputed company in USA Vibrant Life in California.

Intense exchange of ideas & technical information between Emmessar Biotech & Nutrition Ltd., & Vibrant Life, resulted in development of several new concepts and new technologies - combining different schools of thought such as Nutraceuticals, Cosmeceuticals, Ayurveda & Biotechnology.

The company has developed many products covering different areas of healthcare that include obstinate Skin problems & debilitating chronic physical ailments.

Emmessar Biotech & Nutrition Ltd., is a Public Limited Company, with the Paid-up Share Capital of about Rs. 50.00 million (over $ 1.00 million). The Stocks of Emmessar Biotech & Nutrition Ltd., are traded in The Bombay Stock Exchange Ltd.

Product range of the company includes:

Present products

  • Calmcream 
  • Magicream 
  • Supportt Joint  
  • Supportt Bones
  • Micro Nutrients 
  • Speciality Chemicals
  • CC-99  
  • Biosulf  
  • Calmcream  

Products planned to be launched in future

  • Ayurvedic Creams  
  • Nutraceutical Creams
  • Cosmeceutical Creams  
  • Oral Supplements  

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.98%
1 Week
+9.76%
1 Month
+17.72%
3 Month
+133.38%
6 Month
+181.25%
1 Year
+268.30%
2 Year
+280.77%
5 Year
+216.29%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -1.25 -9.32 -17.71 -7.98 -40.75 78.73 36.00 16.42 19.40
Return on Capital Employed (%) -1.12 -9.22 -9.52 -10.49 -59.37 79.46 31.46 9.00 18.87
Return on Assets (%) -0.55 -3.73 -8.60 -5.08 -20.32 44.83 26.93 12.75 14.93

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2 2 2 1 1 2 3 4 4
Non Curr. Liab. 0 0 0 0 1 1 0 0
Curr. Liab. 3 3 0 1 1 0 0 1 1
Minority Int.
Equity & Liab. 5 5 2 2 2 3 4 5 5
Non Curr. Assets 2 2 2 2 1 2 2 2 2
Curr. Assets 3 3 1 1 1 1 1 3 3
Misc. Exp. not W/O
Total Assets 5 5 2 2 2 3 4 5 5

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 3 1 1 2 2 3 1 1 3
Other Income 0 0 0 0 0 1 1 1 1
Total Income 3 1 1 2 2 4 3 2 5
Total Expenditure -3 -1 -1 -2 -2 -2 -2 -1 -4
PBIDT 0 0 0 0 0 1 1 1 1
Interest 0
Depreciation 0 0 0 0 0 0 0 0 0
Taxation 0 0 0 0 0 0
Exceptional Items -1 0 0
PAT 0 0 0 0 0 1 1 1 1

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 0 0 0 1 1 0 1
Cash Fr. Inv. 0 0 0 -1 -1 0 -1
Cash Fr. Finan.
Net Change 0 0 0 0 0 0 0 0
Cash & Cash Eqvt 0 0 0 0 0 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 58.28 58.28 58.46 58.46 58.46 58.46 58.45 58.50 58.51
Public 41.72 41.72 41.54 41.54 41.54 41.54 41.55 41.50 41.49
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 22 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provisions of Regulation 47(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the newspaper clippings regarding the intimation of Board Meeting to be held on Thursday July 29 2021 published in The Free Press Journal in English and Navshakti in Marathi dated 21-07-2021 are attached.

You are kindly requested to take this on record.
Mon, 19 Jul 2021
Intimation Under 30 SEBI (LODR) 2015
Pursuant to Regulation 31A (8) (a) of the SEBI (LODR) 2015 please be informed that requests have been received from constituents of Promoter / Promoter Group as per details attached for re-classification of their shareholding into Public shareholding.

Since there is a cleavage on this aspect these applicants have been informed to obtain informal guidance from SEBI under the SEBI (Informal Guidance) Scheme 2003.
Mon, 19 Jul 2021
Board Meeting Intimation for Notice Of The Meeting Of Board Of Directors Of The Company Under Regulation 29(1)(A) Of SEBI (LODR) Regulations 2015.<BR>
EMMESSAR BIOTECH & NUTRITION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2021 inter alia to consider and approve the Un-Audited Financial Results of the Company for the quarter ended 30.06.2021 which will be subjected to Limited Review.

To discuss any other matter as may be decided by the Board.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%